The Autonomous Critical Care System (ACCS) Zeus™ and the Integrated Combat Casualty Care System (ICCCS) are Office of Naval Research (ONR) programs. Athena GTX®, Inc., as ONR’s prime contractor, is developing the ACCS system into two hybrids. First, the Zeus™ platform is a robust under-litter, self-contained medical care platform with emerging closed loop control and remote control of therapies via cyber secured high speed communications. Secondly, the Integrated Combat Casualty Care System (ICCCS) is a smaller backpack device leveraged extensively from ACCS-Zeus™ that reduces technical risk via wired DROID interface (no wireless communications on the battlefield). Design and development plans follow established Athena GTX® regulatory considerations and FDA inputs as these are designed to integrate MDDS, Class 1 to 2, 510K and PMA approaches and technologies. The resultant adaptive and modular project includes comprehensive engineering integration with many options and capabilities. A novel care provider interface software, CHAT-R™, allows remote medical personnel to see and interface with patients via an encrypted platform.
The Hypoxia Alert and Mitigation System (HAMS) is now in Phase 2. The HAMS II is a full system development of a missionized and robust platform for detection/prediction/ anticipation of hypoxia based on a novel wearable sensing suite incorporating warning and state assessment and will eventually include modes of mitigation. HAMS will enter operational use by both ground troops and CASEVAC. The team of Athena GTX®, Inc. and Criterion Analysis Inc. (CAI), while in cooperation with other HAMS subcontractors to the ONR, is the prime integrator and developer of the product.
The goal of HAMS is to provide optimal protection of military personnel via high speed miniaturized intelligent monitoring and adaptive modeling. HAMS accounts for individual differences in physiologic tolerance and provides a timely warning such that personnel can take corrective action before missions are compromised or injuries aggravated. HAMS will address cognitive and physiological workload at altitude, and the dynamic impact of sustained high altitude operations. Hams operational use will include transitioning to a medical monitoring platform if and when needed. The effort under this program allows for iterative and progressive prototype development with user testing to occur leading to options for development of systems that are FDA cleared and ready for field use.